Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q86968575)
Watch
English
Old drugs, new tricks for triple-negative breast cancer
scientific article published on 18 March 2015
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
title
Old drugs, new tricks for triple-negative breast cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
main subject
triple-negative breast cancer
1 reference
based on heuristic
inferred from title
author name string
Lisa Carey
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
publication date
18 March 2015
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
volume
16
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
issue
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
page(s)
357-359
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
cites work
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRCA1 pathway function in basal-like breast cancer cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970108-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(15)70108-7
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
PubMed publication ID
25795403
1 reference
stated in
Europe PubMed Central
PubMed publication ID
25795403
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795403%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit